Lumos Pharma, Inc.

LUMO

US55028X1090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:28:47 06/06/2024 am IST			5-day change	1st Jan Change
2.35 ^USD	+3.52%		+1.73%	-26.10%

04/06	Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	CI
15/05	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	CI

NewLink Genetics Corporation has Changed its Name to Lumos Pharma, Inc

March 18, 2020 at 09:30 am IST

On March 18, 2020, NewLink Genetics Corporation changed its name to Lumos Pharma, Inc.

Latest news about Lumos Pharma, Inc.

Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	04/06	CI
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	15/05	CI
Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Transcript : Lumos Pharma, Inc., Q1 2024 Earnings Call, May 15, 2024	15/05
Lumos Pharma Plans Phase 3 Study of Growth Hormone Drug	15/05	MT
Earnings Flash (LUMO) LUMOS PHARMA Posts Q1 Revenue $165,000, vs. Street Est of $0.3M	15/05	MT
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024	08/03
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M	08/03	MT
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer	05/01	CI
Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating	11/12	MT
Transcript : Lumos Pharma, Inc. - Special Call	07/12
North American Morning Briefing : Stock Futures -2-	13/11	DJ
Transcript : Lumos Pharma, Inc. - Special Call	08/11
Top Premarket Gainers	08/11	MT
Lumos Pharma Phase 2 Trials Targeting Pediatric Growth Hormone Deficiency Meet Endpoints; Shares Surge Premarket	08/11	MT
Lumos Pharma Shares Than Double After Hormone Deficiency Trial Meets All Endpoints	08/11	DJ
Tranche Update on Lumos Pharma, Inc.'s Equity Buyback Plan announced on August 16, 2022.	08/11	CI
Lumos Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11	CI
Earnings Flash (LUMO) LUMOS PHARMA Posts Q3 Revenue $7,000	08/11	MT
Lumos Pharma, Inc. Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 inPGHD Met All Primary and Secondary Endpoints	08/11	CI
Lumos Pharma Says New Data Shows LUM-201 Restored Growth Hormone Secretion to Similar Levels in Normally Growing Children	26/23/26	MT
Lumos Pharma Announces New Data and Analysis of 15 Subjects from Oragrowth212 Trial Presented At the 2023 ESPE Annual Meeting	26/23/26	CI
Lumos Pharma, Inc. Announces Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting	14/23/14	CI
Transcript : Lumos Pharma, Inc. - Special Call	05/23/05

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.

Sector

Biotechnology & Medical Research

Calendar

12/11/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lumos Pharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.35 USD

Average target price

22.5 USD

Spread / Average Target

+857.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LUMOS PHARMA, INC.	-26.10%	19.07M
MODERNA, INC.	+55.70%	59.34B
LONZA GROUP AG	+41.08%	40.24B
IQVIA HOLDINGS INC.	-5.39%	39.88B
CELLTRION, INC.	-5.56%	28.55B
ICON PUBLIC LIMITED COMPANY	+16.46%	27.26B
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	19.23B
MEDPACE HOLDINGS, INC.	+33.03%	12.61B
UNITED THERAPEUTICS CORPORATION	+25.85%	12.28B
BIO-TECHNE CORPORATION	+2.72%	12.49B

Other Biotechnology & Medical Research

Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Biotechnology & Medical Research

NewLink Genetics Corporation has Changed its Name to Lumos Pharma, Inc

Latest news about Lumos Pharma, Inc.

Chart Lumos Pharma, Inc.

Company Profile

Income Statement Evolution

Ratings for Lumos Pharma, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research